KPV (α-MSH Fragment)

KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment (amino acids 11–13) of α-melanocyte-stimulating hormone (α-MSH). Unlike the full-length 13-amino-acid hormone, KPV does not activate classical melanocortin receptors (MC1R–MC5R) at physiologically relevant concentrations — its anti-inflammatory effects operate through receptor-independent intracellular mechanisms, primarily inhibition of the NF-κB transcription factor pathway.

The core mechanism involves NF-κB pathway inhibition: KPV suppresses IκB kinase (IKK) activity, preventing phosphorylation and proteasomal degradation of IκB-α — the inhibitory protein that sequesters NF-κB in the cytoplasm. When IκB-α degradation is blocked, NF-κB p65/p50 subunits cannot translocate to the nucleus to activate transcription of pro-inflammatory genes (TNF-α, IL-1β, IL-6, COX-2, iNOS). Studies across multiple cell types — intestinal epithelial cells, macrophages, keratinocytes, and chondrocytes — have consistently documented reduced NF-κB DNA-binding activity and downregulated inflammatory gene expression following KPV exposure.

A defining feature of KPV pharmacology is its transport via the PepT1 (SLC15A1) oligopeptide transporter — a proton-coupled transporter in the intestinal brush border membrane that mediates uptake of di- and tripeptides. KPV is a substrate for PepT1, which actively transports it into intestinal epithelial cells, concentrating its anti-inflammatory effects in gastrointestinal tissue. This transport mechanism has two critical implications: (1) it provides a basis for potential oral bioavailability, unlike most peptides requiring injection; (2) it targets the peptide to the intestine, where PepT1 expression is highest — making KPV particularly relevant for inflammatory bowel disease research. Additional mechanisms under investigation include NLRP3 inflammasome modulation (reduced caspase-1 activation and IL-1β secretion) and direct antioxidant effects.

The anti-inflammatory properties of α-MSH were recognized in the 1980s–90s, but the discovery that the C-terminal KPV fragment retained these effects independently of melanocortin receptors catalyzed focused research on the tripeptide. Key publications by Dalmasso et al. (2008, Gastroenterology) demonstrated PepT1-mediated KPV uptake and reduced intestinal inflammation in DSS-colitis models, establishing the gut-directed anti-inflammatory paradigm.

Subsequent studies expanded the profile: nanoparticle-encapsulated KPV showed enhanced efficacy in colitis models (Laroui et al., 2010); keratinocyte studies documented anti-inflammatory effects relevant to dermatological research; and in vitro work confirmed NF-κB inhibition across multiple tissue types. However, human clinical data remains extremely limited — KPV has not advanced to formal clinical trials as of 2026, and all published evidence derives from cell-culture and animal models. The compound occupies an interesting niche as one of the smallest bioactive anti-inflammatory peptides with a plausible oral-uptake mechanism, though the translational gap to human application remains wide.

Store lyophilized KPV at -20°C in a light-protected, desiccated container. As a short, simple tripeptide (Lys-Pro-Val, 342 Da) with no disulfide bonds or complex secondary structure, it is relatively stable — the small size minimizes degradation pathways. Stability exceeds 24 months under optimal conditions.

After reconstitution with bacteriostatic water, KPV should be stored at 2–8°C and used within 21 days. The tripeptide is highly water-soluble — lysine and the ionizable termini confer excellent aqueous solubility at physiological pH. The solution is clear and colorless. For intranasal protocols using sterile saline, use within 14 days due to absence of benzyl alcohol preservative. For oral gavage research protocols, reconstitute immediately before administration. Do not freeze reconstituted solutions.